Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study

Background  Patients with atrial fibrillation (AF) are frequently treated with apixaban 2.5-mg twice daily (BID) off-label, presumably to reduce the bleeding risk. However, this approach has the potential to increase the risk of ischemic stroke. If a single measurement could reliably identify patien...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vries, Tim A.C., Hirsh, Jack, Bhagirath, Vinai C., Ginsberg, Jeffrey S., Pisters, Ron, Hemels, Martin E.W., de Groot, Joris R., Eikelboom, John W., Chan, Noel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786560/
https://www.ncbi.nlm.nih.gov/pubmed/35088021
http://dx.doi.org/10.1055/s-0041-1740492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786560/
https://www.ncbi.nlm.nih.gov/pubmed/35088021
http://dx.doi.org/10.1055/s-0041-1740492

Ejemplares similares